Drug intelligence / Profile preview

PPMX-T004

Development stage: Preclinical
Lead developer: Perseus Proteomics
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

PPMX-T004 is an antibody-drug conjugate (ADC) developed by Perseus Proteomics that targets cadherin-3 (CDH3), also known as P-cadherin. CDH3 is a cell surface glycoprotein overexpressed in various solid tumors, including ovarian cancer, biliary tract cancer, and squamous cell carcinomas, while having limited expression in normal tissues. The drug consists of a CDH3-specific antibody conjugated to a cytotoxic payload. Upon binding to CDH3 on the tumor cell surface, the ADC is internalized, and the payload is released to induce cell death. Perseus Proteomics has licensed the clinical development of PPMX-T004 to Fujifilm Group.

Other names: P-cadherin antibody-drug conjugate

Targets

CDH3 (Cadherin-3)

Beyond the preview

Go deeper on PPMX-T004.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PPMX-T004.

Explore the full profile